Literature DB >> 8852407

Induction of anti-malarial transmission blocking immunity with a recombinant ookinete surface antigen of Plasmodium berghei produced in silkworm larvae using the baculovirus expression vector system.

H Matsuoka1, J Kobayashi, G C Barker, K Miura, Y Chinzei, S Miyajima, A Ishii, R E Sinden.   

Abstract

We have studied Pbs21, a major ookinete surface protein of Plasmodium berghei, for the development of a model transmission blocking immunogen. In the mouse, recombinant Pbs21 expressed in the Escherichia coli expression system (EcrPbs21) is not as effective in inducing transmission blocking antibodies as native Pbs21 (nPbs21), possibly because of differences in post-translational processing between EcrPbs21 and nPbs21. In an attempt to improve the efficacy of the recombinant molecule, we describe here the use of a baculovirus expression vector system in the silkworm Bombyx mori. Following an injection of recombinant baculovirus containing Pbs21 cDNA, B. mori larvae produced recombinant Pbs21 (BmrPbs21) with a molecular weight indistinguishable from nPbs21. Fifty micrograms of BmrPbs21 could be purified from the hemolymph of each infected larva using affinity chromatography. Immunization of Balb/c mice with BmrPbs21 induced high anti-BmrPbs21 and anti--ookinete antibodies but low anti-EcrPbs21 antibody. In contrast, EcrPbs21 induced high anti--EcrPbs21 antibody but low anti-BmrPbs21 and anti-ookinete antibodies. This suggests that most B-cell epitopes on nPbs21 are conformational and that many of the linear epitopes in EcrPbs21 are not normally exposed in nPbs21. Oocyst formation in Anopheles stephensi mosquitoes, which fed on mice immunized with purified BmrPbs21 and infected with P. berghei, was blocked by 85.5-97.1%. These results suggest that the baculovirus-silkworm system produces useful quantities of recombinant Pbs21 which in limited studies is structurally and immunogenically indistinguishable from the native molecule.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8852407     DOI: 10.1016/0264-410x(95)00162-t

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  6 in total

1.  Delivery strategies for novel vaccine formulations.

Authors:  Maria Trovato; Shelly J Krebs; Nancy L Haigwood; Piergiuseppe De Berardinis
Journal:  World J Virol       Date:  2012-02-12

2.  Transgenic expression of a mosquito-stage malarial protein, Pbs21, in blood stages of transformed Plasmodium berghei and induction of an immune response upon infection.

Authors:  G Margos; M R van Dijk; J Ramesar; C J Janse; A P Waters; R E Sinden
Journal:  Infect Immun       Date:  1998-08       Impact factor: 3.441

3.  A novel model fitted to multiple life stages of malaria for assessing efficacy of transmission-blocking interventions.

Authors:  Ellie Sherrard-Smith; Thomas S Churcher; Leanna M Upton; Katarzyna A Sala; Sara E Zakutansky; Hannah C Slater; Andrew M Blagborough; Michael Betancourt
Journal:  Malar J       Date:  2017-04-04       Impact factor: 2.979

Review 4.  Vaccines for viral and parasitic diseases produced with baculovirus vectors.

Authors:  Monique M van Oers
Journal:  Adv Virus Res       Date:  2006       Impact factor: 9.937

5.  The utility of Plasmodium berghei as a rodent model for anti-merozoite malaria vaccine assessment.

Authors:  Anna L Goodman; Emily K Forbes; Andrew R Williams; Alexander D Douglas; Simone C de Cassan; Karolis Bauza; Sumi Biswas; Matthew D J Dicks; David Llewellyn; Anne C Moore; Chris J Janse; Blandine M Franke-Fayard; Sarah C Gilbert; Adrian V S Hill; Richard J Pleass; Simon J Draper
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

6.  Rotavirus A-specific single-domain antibodies produced in baculovirus-infected insect larvae are protective in vivo.

Authors:  Silvia Gómez-Sebastián; Maria C Nuñez; Lorena Garaicoechea; Carmen Alvarado; Marina Mozgovoj; Rodrigo Lasa; Alan Kahl; Andres Wigdorovitz; Viviana Parreño; José M Escribano
Journal:  BMC Biotechnol       Date:  2012-09-07       Impact factor: 2.563

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.